Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
State University of New York at Buffalo
With
Genentech, Inc.
To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient participating in the ORATORIO study
MRI scans available at baseline
Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline
